Biomarker ID | 930 |
PMID | 22615945 |
Year | 2012 |
Biomarker | Triosephosphate isomerase 1 (TPI1); Spondin-2 (SPON-2); Thrombospondin 1, N-Terminal Domain (THBS1); Phosphoglycerate mutase 1 (PGAM1); Syndecan binding protein 1 (ST1); Peroxiredoxin 1 (PRDX1); Nucleophosmin- isoform CRA_c (NPM1) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Cell Lines |
Regulation | Differentially Expressed in PCA |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | BPH-1, LNCaP Vs C4-2 |
Type of Biomarker | Diagnostic |
Cohort | 3 Prostate cancer Cell lines: BPH-1, LNCaP and C4-2 were taken into consideration for this study. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | two-dimensional gel electrophoresis (2-DE) coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Cohort |
Technical Name | TPI1, SPON2, THBS1, PGAM1, NPM1 |